Can-Fite BioPharma Ltd.
CANFAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 2, 2026 | H.C. Wainwright | $8.00(+73%) | $4.63 | StreetInsider | |
| May 12, 2026 | H.C. Wainwright | Swayampakula Ramakanth | $5.00(+49%) | $3.36 | TheFly |
| Apr 15, 2025 | Industrial Alliance Securities | James Molloy | $4.50(-86%) | $31.40 | TheFly |
| Jul 17, 2024 | EF Hutton | Jason Kolbert | $10.00(-86%) | $73.20 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jul 2, 2026 |
| D. Boral Capital | upgrade | Hold →Buy | May 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2026 |
| D. Boral Capital | downgrade | Buy →Hold | Dec 24, 2025 |
| D. Boral Capital | maintain | Buy | Dec 17, 2025 |
| D. Boral Capital | maintain | Buy | Nov 18, 2025 |
| D. Boral Capital | maintain | Buy | Sep 16, 2025 |
| D. Boral Capital | maintain | Buy | Sep 2, 2025 |
| D. Boral Capital | maintain | Buy | Jul 29, 2025 |
| D. Boral Capital | maintain | Buy | Apr 15, 2025 |
| D. Boral Capital | maintain | Buy | Mar 21, 2025 |
| D. Boral Capital | maintain | Buy | Mar 20, 2025 |
| D. Boral Capital | maintain | Buy | Mar 18, 2025 |
| D. Boral Capital | maintain | Buy | Mar 3, 2025 |
| D. Boral Capital | maintain | Buy | Feb 18, 2025 |
| D. Boral Capital | maintain | Buy | Dec 31, 2024 |
| D. Boral Capital | maintain | Buy | Dec 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 24, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 2, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 13, 2023 |
| H.C. Wainwright | maintain | Buy | Sep 24, 2019 |
| Maxim Group | downgrade | Buy →Hold | Mar 9, 2018 |
| Maxim Group | maintain | Buy | Aug 11, 2017 |
Earnings History
Next report: Apr 1, 2027 · EPS est. $-0.80| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 8, 2026 | $-1.24 | $-0.33 | $202.0K | $300.0K |
| Mar 26, 2026 | $-5.97 | $-27.00 | $203.0K | $300.0K |
| Aug 28, 2025 | $-0.00 | $-4.15 | $202.0K | $500.0K |
| Apr 14, 2025 | $-0.10 | $-0.10 | $101.0K | $500.0K |
| Mar 27, 2025 | $-0.00 | $-0.24 | $179.0K | $150.0K |
| Jan 2, 2025 | $-0.27 | $-0.27 | $300.0K | $150.0K |
| Aug 29, 2024 | $-0.00 | $-0.36 | $100.0K | $300.0K |
| Jul 4, 2024 | $-0.00 | $-0.40 | $300.0K | $300.0K |
News
Company to leverage positive Phase IIa pancreatic cancer results presented at ESMO 2026, two pivotal Phase III programs, and expanding patent protection to advance global partnering opportunities
Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat Gan, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Eurasian Patent Office (EAPO) has is…
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients One second-line patient achieved progression-free survival of 16.39 months and overall survival exceeding 20.7 months RAMAT GAN, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing small molecule therapeutics targeting cancer and inflammatory diseases, today announced the presentation of …
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise…
Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemo…
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today provided an update on the regulatory status of its two lead drug candidates, Piclidenoson…